Cite
Comparison of clinical efficacy and safety of weekly glucagon‐like peptide‐1 receptor agonists dulaglutide and semaglutide in Japanese patients with type 2 diabetes: Randomized, parallel‐group, multicentre, open‐label trial (COMING study)
MLA
Kimura, Tomohiko, et al. “Comparison of Clinical Efficacy and Safety of Weekly Glucagon‐like Peptide‐1 Receptor Agonists Dulaglutide and Semaglutide in Japanese Patients with Type 2 Diabetes: Randomized, Parallel‐group, Multicentre, Open‐label Trial (COMING Study).” Diabetes, Obesity & Metabolism, vol. 25, no. 12, Dec. 2023, pp. 3632–47. EBSCOhost, https://doi.org/10.1111/dom.15258.
APA
Kimura, T., Katakura, Y., Shimoda, M., Kawasaki, F., Yamabe, M., Tatsumi, F., Matsuki, M., Iwamoto, Y., Anno, T., Fushimi, Y., Kamei, S., Kimura, Y., Nakanishi, S., Mune, T., Kaku, K., & Kaneto, H. (2023). Comparison of clinical efficacy and safety of weekly glucagon‐like peptide‐1 receptor agonists dulaglutide and semaglutide in Japanese patients with type 2 diabetes: Randomized, parallel‐group, multicentre, open‐label trial (COMING study). Diabetes, Obesity & Metabolism, 25(12), 3632–3647. https://doi.org/10.1111/dom.15258
Chicago
Kimura, Tomohiko, Yukino Katakura, Masashi Shimoda, Fumiko Kawasaki, Mizuho Yamabe, Fuminori Tatsumi, Michihiro Matsuki, et al. 2023. “Comparison of Clinical Efficacy and Safety of Weekly Glucagon‐like Peptide‐1 Receptor Agonists Dulaglutide and Semaglutide in Japanese Patients with Type 2 Diabetes: Randomized, Parallel‐group, Multicentre, Open‐label Trial (COMING Study).” Diabetes, Obesity & Metabolism 25 (12): 3632–47. doi:10.1111/dom.15258.